Another face of placebo: The lessebo effect in Parkinson disease

Neurology

Volumn 82, Issue 16, 2014, Pages 1402-1409

  Mestre, Tiago A ^a,d,f   Shah, Prakesh ^b,e   Marras, Connie ^a,d   Tomlinson, George ^c,d   Lang, Anthony E ^a,d  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; ANTIPARKINSON AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; LESSEBO EFFECT; META ANALYSIS; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PARKINSON DISEASE; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNIFIED PARKINSON DISEASE RATING SCALE; AGED; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; PSYCHOLOGICAL ASPECT;

AGED; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901935304     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000340     Document Type: Article

References (27)

1. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008; 23: 690-699.
2. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant? J Clin Psychiatry 2010; 71: 270-279.
3. Moncrieff J. A comparison of antidepressant trials using active and inert placebos. Int J Methods Psychiatr Res 2003; 12: 117-127. (Pubitemid 37168549)
4. Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry 2005; 62: 961-970. (Pubitemid 41248375)
5. Sneed JR, Rutherford BR, Rindskopf D, Lane DT, Sackeim HA, Roose SP. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry 2008; 16: 65-73.
6. Henkel V, Casaulta F, Seemuller F, et al. Study design features affecting outcome in antidepressant trials. J Affect Disord 2012; 141: 160-167.
7. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26(suppl 3):S42-S80.
8. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58: 11-17. (Pubitemid 34041931)
9. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-995. (Pubitemid 44044780)
10. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES): part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1202. (Pubitemid 44581465)
11. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-539. (Pubitemid 40862249)
12. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES): part I: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1185. (Pubitemid 44581464)
13. Nieuwboer A, Odin P, Poewe W, et al. Late (complicated) Parkinson's disease. In: Gilhus NE, Barnes MP, Brainin M, eds. European Handbook of Neurological Management, 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2011.
14. Oertel WH, Berardelli A, Bloem BR, et al. Early (uncomplicated) Parkinson's disease. In: Gilhus NE, Barnes MP, Brainin M, eds. European Handbook of Neurological Management, 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2011.
15. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available at: http://handbook.cochrane.org/. Accessed March 12, 2014.
16. The Nordic Cochrane Centre TCC. Review Manager (RevMan) [Computer program], Version 5.1. Oxford: The Nordic Cochrane Centre TCC; 2011.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
18. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
19. Hauser RA, Auinger P, Group PS. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011; 26: 813-818.
20. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the Unified Parkinson's Disease Rating Scale. Mov Disord 2006; 21: 1200-1207. (Pubitemid 44336608)
21. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
22. De La Fuente-Fernández R, Stoessl AJ. The biochemical bases for reward: implications for the placebo effect. Eval Health Prof 2002; 25: 387-398. (Pubitemid 36950485)
23. de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166. (Pubitemid 32758101)
24. Goetz CG, Janko K, Blasucci L, Jaglin JA. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord 2003; 18: 1146-1149. (Pubitemid 37336938)
25. Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010; 67: 857-865.
26. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-1573. (Pubitemid 34746063)
27. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.